Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with STELARA.
应评估病人对结核病 （TB）的感染前主动与其STELARA治疗。
These data show the consistency of response with STELARA in the treatment of psoriasis across ethnic populations.
这些数据显示，与STELARA反应在不同种族人群的治疗牛皮癣的一致性。
Ongoing studies in psoriasis and psoriatic arthritis will continue to define the safety profile of STELARA in the psoriatic population.
正在进行的牛皮癣和银屑病性关节炎的研究将继续定义在银屑病人口的STELARA的安全性。
STELARA patients received a third dose at week 16, while placebo-treated patients crossed over to receive active treatment at weeks 12 and 16.
STELARA患者接受16周三分之一剂量，而安慰剂治疗的患者越过收到12至16周时积极治疗。
These responses continued to improve through week 28 across groups, with similar responses seen in placebo-treated patients following crossover to treatment with STELARA.
这些反应持续28周来改善各组，与安慰剂治疗的患者出现类似下面的交叉反应，与STELARA治疗。
Caution should be exercised when considering the use of STELARA in patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy.
应谨慎行事时考虑STELARA患者使用一个恶性历史或在考虑继续在病人谁患上恶性肿瘤的治疗。
In the four analyzed studies, patients received subcutaneous injections of STELARA 45 mg or 90 mg, or placebo at weeks 0 and 4, although only the STELARA 45 mg dose was evaluated in the PEARL trial.
在四个分析研究，患者接受0和4周的STELARA45毫克或90毫克，皮下或安慰剂注射，虽然只有45毫克剂量stelara在珠江三角洲研究评估。
STELARA-treated patients also demonstrated clinically meaningful improvements in quality of life, as measured by the Dermatology life quality Index (DLQI), at weeks 12 and 28 across the four trials.
STELARA治疗的患者也表现出临床意义的改善，生活质量，按照皮肤病生活质量指数(DLQI)，测量12周时在四个试验28。
STELARA-treated patients also demonstrated clinically meaningful improvements in quality of life, as measured by the Dermatology life quality Index (DLQI), at weeks 12 and 28 across the four trials.
STELARA治疗的患者也表现出临床意义的改善，生活质量，按照皮肤病生活质量指数(DLQI)，测量12周时在四个试验28。
应用推荐